Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
PMI vs PRE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PMI Captures Overall Composite Edge (48.4 HOLD vs 40.8 SELL), While PRE Leads 3–1 on Growth & Valuation Pillars
PMI Overall Winner
6-Pillar Tally: PMI 1 – 3 PRE (2 Tie)
Matrix Metrics: PMI 6 – 3 PRE
As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Prenetics Global Limited Class A Ordinary Share (PRE) on higher Unified Composite conviction (48.4/100 HOLD vs. 40.8/100 SELL) after splitting the core matrix 6–3 (led by Options & Positioning), while PRE wins 3–1 across the 6-pillar growth and valuation breakdown. PMI trades at $6.30 (N/M Forward P/E, -248.1% operating margin) versus PRE at $10.31 (N/M Forward P/E, -32.5% operating margin).
- Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. PRE 40.8/100 SELL) and 54.06β · 134% Vol risk profile, whereas PRE leads top-line expansion (+172.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1); meanwhile PRE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PMI vs PRE
PMI
Head-to-Head Winner
Picard Medical, Inc.
$6.30
-2.17% 1D
Market Cap
$17.1M
TTM Revenue
$6.3M
Forward P/E
N/M
Beta / 30D Vol
54.06β · 134% Vol
Unified Composite Score
48.4
HOLD
Tech 39.0
Fund 45.0
Flow 50.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
PRE
Prenetics Global Limited Class A Ordinary Share
$10.31
-0.39% 1D
Market Cap
$205.5M
TTM Revenue
$199M
Forward P/E
N/M
Beta / 30D Vol
1.66β · 141% Vol
Unified Composite Score
40.8
SELL
Tech 25.0
Fund 45.0
Flow 55.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (PMI 1 – 3 PRE)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
2.9x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
3.2x
0.7x
2. Growth & Scale
PRE
Revenue Growth (YoY)
+38.6%
+172.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$6.3M
$199M
Market Cap
$17.1M
$205.5M
3. Profitability & Quality
PRE
Gross Margin
18.6%
58.1%
Operating Margin
-248.1%
-32.5%
Net Profit Margin
0.0%
-32.6%
Return on Equity (ROE)
0.0%
-67.8%
4. Balance Sheet & Cash Flow
PRE
Cash Generation (TTM)
-$17M
-$66M EBITDA
Cash Flow Margin
N/A
-33.4% EBITDA Mgn
Net Cash / Leverage
$3.2M Net Debt
$58M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
PMI
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
89.5% (13th %ile)
Put/Call OI Skew
N/A
0.49x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Packaged Foods Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PMI (6) vs PRE (3)| Institutional Metric | PMI | PRE | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $17.1M | $205.5M | PRE | |
| Trailing P/E Ratio | 2.9x | N/M | PMI | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +38.6% | +172.2% | PRE | |
| Operating Margin (TTM) | -248.1% | -32.5% | PRE | |
| Net Profit Margin | 0.0% | -32.6% | PMI | |
| Return on Equity (ROE) | 0.0% | -67.8% | PMI | |
| 52-Week Range Position | 34% ($0–$18) | 6% ($9–$27) | PMI | |
| Beta / 30D Volatility | 54.06β · 134% Vol | 1.66β · 141% Vol | PMI | |
| Unified Institutional Score | 48.4 / 100 (HOLD) | 40.8 / 100 (SELL) | PMI | |
| Trailing 12M Revenue (USD) | $6.3M | $199M | Scale | |
| Gross Profit Margin (TTM) | 18.6% | 58.1% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 3.2x EV/Rev | N/M PEG · 0.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$17M ($3.2M Net Debt) | -$66M EBITDA ($58M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PMI +3.79 pp
3M Horizon
PMI +145.22 pp
6M Horizon
PMI +3482.02 pp
1Y Horizon
PMI +164.31 pp
Financial Trajectory Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)
| Period | PMI Revenue | PRE Revenue | PMI Op. Margin | PRE Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| Q2 '25 | $10M | $50M | -165.2% | -70.0% | PRE |
| Q3 '25 | $0M | $90M | -293.8% | -27.8% | PRE |
| Q4 '25 | $0M | $150M | -297.6% | -35.9% | PRE |
| Q1 '26 | $0M | $140M | -392.3% | -27.0% | PRE |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PMI
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
PRE
BREAKDOWN
Current IV
89.5%
IV Percentile
13th %ile
Put/Call OI Skew
0.49x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact PRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PMI Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
PRE Moat Profile
Cyclical / Execution-Driven Positioning
Packaged Foods Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ PMI vs PRE Key Questions & Quantitative Answers
As of Nov 19, 2026, Picard Medical, Inc. (PMI) captures the overall head-to-head institutional edge over Prenetics Global Limited Class A Ordinary Share (PRE) on higher Unified Composite conviction (48.4/100 HOLD vs. 40.8/100 SELL) after splitting the core matrix 6–3 (led by Options & Positioning), while PRE wins 3–1 across the 6-pillar growth and valuation breakdown. PMI trades at $6.30 (N/M Forward P/E, -248.1% operating margin) versus PRE at $10.31 (N/M Forward P/E, -32.5% operating margin). Growth vs. Quality Trade-Off: PMI earns the overall head-to-head edge with a stronger Unified Composite Score (48.4/100 HOLD vs. PRE 40.8/100 SELL) and 54.06β · 134% Vol risk profile, whereas PRE leads top-line expansion (+172.2% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1); meanwhile PRE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PRE leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with PRE at +172.2% YoY revenue growth and +0.0% YoY earnings growth on $199M TTM revenue (58.1% gross margin, -32.5% operating margin). Across the 4-period historical trajectory (Q2 '25 to Q1 '26), PMI cumulative revenue shifted N/A while PRE shifted +180.0%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PRE.
PMI and PRE trade at balanced relative valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas PRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-33.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus PRE (-67.8% ROE) capital efficiency.
In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, PRE carries 89.5% implied volatility (13th %ile, Compressed (<25th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.66β · 141% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
PRE vs PMI · Reverse Pair
PMI vs RDN
· Sector Peer
PMI vs MTG
· Sector Peer
PMI vs MBI
· Sector Peer
PRE vs RNR
· Sector Peer
PRE vs AXS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem